The Children's Hospital Receives $50,000 Donation Through The CRESTOR(R) Charity Challenge at PGA TOUR's The INTERNATIONAL
August 07 2005 - 6:58PM
PR Newswire (US)
- Brandt Jobe Wins for Charity - CASTLE ROCK, Colo., Aug. 7
/PRNewswire/ -- Brandt Jobe was named this week's CRESTOR(R)
(rosuvastatin calcium) Charity Challenge winner for his first-place
standing entering the final round of The INTERNATIONAL. The
CRESTOR(R) Charity Challenge is a season-long competition that
recognizes and rewards the tournament leader entering the final
round at 35 PGA TOUR events. Through the program, now in its second
year, AstraZeneca will donate $3.5 million a year to designated
health and PGA TOUR charities. At each of the selected tournaments,
a $100,000 contribution will be made, supporting the PGA TOUR's
"Drive to a Billion" campaign which celebrates the spirit of giving
that has helped the TOUR and its tournaments approach the milestone
of $1 billion dollars in charitable giving. For Jobe's performance,
CRESTOR, an AstraZeneca pharmaceutical product, and The
INTERNATIONAL will donate $50,000 to The Children's Hospital in
Denver. In addition, $50,000 will be donated to the health care
charity of Jobe's choice. CRESTOR(R) Charity Challenge winners and
the tournament's designated charity will be recognized during the
network or cable telecast of each tournament. Last year, Chris
DiMarco and Rod Pampling were in the lead entering the final round
of The INTERNATIONAL. For their performance, AstraZeneca donated
$50,000 to the University of Colorado Hospital. DiMarco donated
$15,000 to the American Cancer Society and $10,000 to the Cystic
Fibrosis Center, and Pampling donated $15,000 to the Cystic
Fibrosis Center and $10,000 to the University of Colorado Hospital.
"All of us at The Children's Hospital are excited, pleased, and
grateful that this year's CRESTOR(R) Charity Challenge donation is
going to help us in our mission to improve the health of children
through excellent, coordinated programs of patient care, research,
education and advocacy," said Don Elliman, Chair of The Children's
Hospital Board of Directors. The CRESTOR(R) (rosuvastatin calcium)
Charity Challenge is the centerpiece of a multi-year PGA TOUR
partnership with AstraZeneca (NYSE:AZN). Last year, AstraZeneca
donated $2.7 million through the program. Highlights from the
CRESTOR(R) Charity Challenge include -- Vijay Singh won last week's
CRESTOR(R) Charity Challenge at the Buick Open in Flint and now has
eight CRESTOR(R) Charity Challenge triumphs overall since 2004 --
Phil Mickelson leads all players in 2005 with three (3) CCC
victories. (Buick Invitational, AT&T Pebble Beach and Ford
Championship at Doral) -- The other multiple CRESTOR(R) Charity
Challenge winners in 2005 are Luke Donald and Vijay Singh, who have
each won twice -- Singh has now won eight (8) CRESTOR(R) Charity
Challenges since the program's inception in 2004 resulting in
$350,000 to the charities of his choice -- $150,000 of which was
donated to the American Red Cross Hurricane Relief Fund (Singh tied
for the lead entering the final round at two tournaments) "After
just one year, the CRESTOR(R) Charity Challenge has become a
visible extension of the PGA TOUR's mission of giving back in local
communities throughout America," said Tony Zook, senior vice
president, commercial operations, AstraZeneca. "Through the support
of AstraZeneca, the CRESTOR(R) Charity Challenge will play a major
role in the PGA TOUR's 'Drive to a Billion' charitable program."
Fans can log on to http://www.crestor.pgatour.com/ to read about
past CRESTOR(R) Charity Challenge winners and learn more about
CRESTOR. CRESTOR is the presenting sponsor of TOUR Fantasy Golf at
http://www.pgatour.com/fantasy and the PGA TOUR's year-end charity
special that will air in December. About The Children's Hospital
Founded in 1908, The Children's Hospital is a private,
not-for-profit pediatric health-care network dedicated 100 percent
to caring for kids. It has been ranked one of the best children's
hospitals in America by U.S. News & World Report and Child
Magazine. With more than 600 experienced experts representing
pediatric specialties, and more than 2,900 full-time employees,
Children's is home to a number of nationally and internationally
recognized medical programs. From medical breakthroughs to
late-night fevers, Children's provides complete pediatric care at
its main campus and through a network that includes eleven
Children's Care Centers and more than 400 outreach clinics held in
three states each year. For more information, visit the web site at
http://www.thechildrenshospital.org/ About CRESTOR CRESTOR
(rosuvastatin calcium) is a once-daily prescription medication for
use as an adjunct to diet in the treatment of various lipid
disorders including primary hypercholesterolemia, mixed
dyslipidemia and isolated hypertriglyceridemia. It is a member of
the statin (HMG-CoA reductase inhibitors) class of drug therapy.
CRESTOR has not been determined to prevent heart disease, heart
attacks, or strokes. For patients with hypercholesterolemia and
mixed dyslipidemia, the usual recommended starting dose of CRESTOR
is 10 mg. However, initiation of therapy with 5 mg once daily
should be considered for patients requiring less aggressive LDL-C
reductions or who have predisposing factors for myopathy, and for
special populations such as patients taking cyclosporine, Asian
patients, and patients with severe renal insufficiency. For
patients with marked hypercholesterolemia (LDL-C >190 mg/dL) and
aggressive lipid targets, a 20-mg starting dose may be considered.
AstraZeneca licensed worldwide rights to CRESTOR from the Japanese
pharmaceutical company Shionogi & Co., Ltd. Important Safety
Information CRESTOR is contraindicated in patients with active
liver disease or unexplained persistent elevations of serum
transaminases, in women who are pregnant or may become pregnant,
and in nursing mothers. It is recommended that liver function tests
be performed before and at 12 weeks following both the initiation
of therapy and any elevation of dose, and periodically (e.g.,
semiannually) thereafter. Rare cases of rhabdomyolysis with acute
renal failure secondary to myoglobinuria have been reported with
CRESTOR and with other drugs in this class. The 40-mg dose of
CRESTOR is reserved only for those patients who have not achieved
their LDL-C goal utilizing the 20 mg dose of CRESTOR once daily.
When initiating statin therapy or switching from another statin
therapy, the appropriate CRESTOR starting dose should first be
utilized, and only then titrated according to the patient's
individualized goal of therapy. The benefit of further alterations
in lipid levels by the combined use of rosuvastatin with fibrates
or niacin should be carefully weighed against the potential risks
of this combination. Combination therapy with rosuvastatin and
gemfibrozil should generally be avoided. CRESTOR should be
prescribed with caution in patients with predisposing factors for
myopathy, such as renal impairment, advanced age, and inadequately
treated hypothyroidism. Patients should be advised to promptly
report unexplained muscle pain, tenderness, or weakness,
particularly if accompanied by malaise or fever. CRESTOR is
generally well-tolerated. Adverse reactions have usually been mild
and transient. The most frequent adverse events thought to be
related to CRESTOR were myalgia (3.3%), constipation (1.4%),
asthenia (1.3%), abdominal pain (1.3%) and nausea (1.3%). A full
copy of the prescribing information for CRESTOR is available at
http:/www.astrazeneca-us.com/pi/crestor.pdf or by calling
1-877-420-7249. About AstraZeneca AstraZeneca is a major
international health care business engaged in the research,
development, manufacture, and marketing of prescription
pharmaceuticals and the supply of health care services. It is one
of the world's leading pharmaceutical companies with health care
sales of over $21.4 billion and leading positions in sales of
gastrointestinal, cardiovascular, respiratory, oncology, and
neuroscience products. In the United States, AstraZeneca is a $9.6
billion health care business with more than 12,000 employees.
AstraZeneca is listed in the Dow Jones Sustainability Index
(Global) as well as the FTSE4Good Index. For more information about
AstraZeneca, please visit: http://www.astrazeneca-us.com/
DATASOURCE: AstraZeneca CONTACT: Chris Smith, PGA TOUR,
+1-904-273-3379, ; or Kellie Caldwell, AstraZeneca, +1-302-885-1435
Web site: http://www.crestor.pgatour.com/
http://www.astrazeneca-us.com/
Copyright